Ebenezer E Satyaraj

US Patent:

20040009503, Jan 15, 2004

Filed:

Mar 26, 2003

Appl. No.:

10/396317

Inventors:

Qin Fu - Baltimore MD, US
Velizar Tchernev - Branford CT, US
Ebenezer Satyaraj - Hamden CT, US
Dhavalkumar Patel - Durham NC, US
Stephen Kingsmore - Guilford CT, US
Barry Schweitzer - Woodbridge CT, US

Assignee:

Molecular Staging, Inc. - New Haven CT

International Classification:

C12Q001/68

US Classification:

435/006000

Abstract:

Human extracellular ribonucleases (RNases) are widely distributed in various organs and body fluids and together with other members of the mammalian RNase A superfamily. In addition to their RNase activity, several RNases have been shown to have special biological actions, i.e., antitumor, antiviral and angiogenic properties. However, the molecular mechanisms of such activities are unclear. Using protein microarrays amplified rolling circle amplification (RCA), we investigated the effects of EDN (Rnase 2), ECP (Rnase 3) and RNase 1 on leukocytes cytokine production. We measured the levels of 78 different cytokines and growth factors in culture supernatants to determine the cytokine profiles of cells treated with different combinations of RNases and RNase inhibitors. Members of human ribonuclease family (such as Rnase 1, hEDN (Rnase 2) and Rnase 3) induced expression of certain sets of cytokines in human leukocytes, including ENA-78, EOT2, BLC, GDNF, 1309, IFN-, IFN-, IL-10, IL-12P40, IL-12p70, IL-13, IL-16, IL-18, IL-1, IL-1ra, IL-2Sra, IL-3, IL-6, IL-6sR, IL-7, IL-8, IP-10, MCP-1, MCP-2, MCP-3, MCSF, MIG, MDC, MIP-1, MIP-1, MPIF-1, NAP-2, RANTES, sCD23, OSM, TARC, TNF-, TNF-R1 and uPAR. Thus members of the Rnase superfamily are therapeutic targets for treatment of inflammatory diseases and clinical conditions. Inhibition or augmentation of Rnase expression is used to modulate the immune system and is beneficial for host defense against various diseases and is exploited as an adjuvant. The expression of Rnases is a diagnostic marker for inflammation related conditions and is used to determine various disease stages. In addition, expression of cytokines, chemokines, growth factors is used to monitor efficacy of Rnase-base therapies.

US Patent:

20040101510, May 27, 2004

Filed:

Sep 12, 2003

Appl. No.:

10/660734

Inventors:

Qin Fu - Baltimore MD, US
Velizar Tchernev - Branford CT, US
Ebenezer Satyaraj - Hamden CT, US
Dhavalkumar Patel - Chapel Hill NC, US
Stephen Kingsmore - Guilford CT, US

Assignee:

Molecular Staging Inc. - New Haven CT

International Classification:

A61K038/19

US Classification:

424/085100

Abstract:

We measured the levels of 78 different cytokines and growth factors in culture supernatants to determine the cytokine profiles of cells treated with PARC. We found that specific cytokines were suppressed by PARC. PARC can be used to treat diseases such as cancer, autoimmune diseases, rheumatoid arthritis, myeloproliferative disorders, and coronary artery disease, which are characterized by too much mitosis.

US Patent:

20070098744, May 3, 2007

Filed:

Oct 6, 2006

Appl. No.:

11/544120

Inventors:

Ruth Knorr - Bussy-les-Daours, FR
Christoph Cavadini - Corsiers-sur-Vevey, CH
Jalil Benyacoub - Lausanne, CH
Ebenezer Satyaraj - Wildwood MO, US

Assignee:

NESTEC S.A. - Vevey

International Classification:

A61K 39/02

US Classification:

424234100

Abstract:

Compositions and methods for modulating immunity and vaccine efficacy in animals are disclosed. The compositions and methods utilize probiotic organisms, specifically probiotic strains, and are particularly applicable to felines.

US Patent:

20070280964, Dec 6, 2007

Filed:

May 24, 2007

Appl. No.:

11/805813

Inventors:

Ruth Knorr - Sailly le Sec, FR
Christoph Cavadini - Corsier-sur-Vevey, CH
Jalil Benyacoub - Lausanne, CH
Ebenezer Satyaraj - Wildwood MO, US

International Classification:

A61K 39/02
A61K 35/74
A61P 27/02
A61P 31/22

US Classification:

424234100, 424093400

Abstract:

Compositions and methods useful for modulating immunity, enhancing vaccine efficacy, decreasing morbidity associated with chronic FHV-1 infections, and/or preventing or treating conjunctivitis in animals. The compositions contain effective amounts of probiotic bacteria and the methods involve administering such compositions to animals alone, in supplements, or in food compositions in amounts suitable for the intended purpose. In certain embodiments, the probiotic is strain NCIMB 10415 (SF68) and the animal is a feline.

US Patent:

20100196880, Aug 5, 2010

Filed:

Oct 4, 2007

Appl. No.:

12/311542

Inventors:

Ebenezer Satyaraj - Wildwood MO, US
Steven S. Hannah - Chesterfield MO, US

International Classification:

C12Q 1/68
C07H 21/04

US Classification:

435 6, 536 2431

Abstract:

Multiplex assays are provided including panels of probes for development of multiplex assays capable of simultaneously measuring multiple biologically-relevant proteins using very small quantities of biological samples to rapidly assess the health status of animals, especially companion animals, as well as to formulate nutritional regimens for improving the health status of animals. The probes are provided as are methods for using them to assess the health status of animals, as well as their responses to therapeutic or nutritional interventions therein.

US Patent:

20120122717, May 17, 2012

Filed:

Nov 15, 2011

Appl. No.:

13/296751

Inventors:

Ebenezer Satyaraj - Wildwood MO, US
Steven S. Hannah - Chesterfield MO, US

Assignee:

Nestec S.A. - Vevey

International Classification:

C40B 30/04

US Classification:

506 9

Abstract:

Multiplex assays are provided including panels of probes for development of multiplex assays capable of simultaneously measuring multiple biologically-relevant proteins using very small quantities of biological samples to rapidly assess the health status of animals, especially companion animals, as well as to formulate nutritional regimens for improving the health status of animals. The probes are provided as are methods for using them to assess the health status of animals, as well as their responses to therapeutic or nutritional interventions therein.

US Patent:

20140004205, Jan 2, 2014

Filed:

Mar 12, 2012

Appl. No.:

14/004947

Inventors:

Ebenezer Satyaraj - Wildwood MO, US

Assignee:

Nestec SA - Vevey

International Classification:

A61K 35/60
A61K 31/381
A61K 31/198
A61K 35/20

US Classification:

424523

Abstract:

The invention provides methods and compositions useful for ameliorating age related maladies, enhancing and maintaining immune function, enhancing and maintaining cognitive function, enhancing and maintaining muscle strength, enhancing and maintaining balance, and reducing and mitigating oxidative stress in an animal. The compositions comprise a combination of at least two of one or more unsaturated fatty acids (UFA); one or more nitric oxide releasing compounds (NORC); one or more anti-glycation agents; and colostrum, and the methods comprise administering to an animal a therapeutically effective amount of the compositions.

US Patent:

8454953, Jun 4, 2013

Filed:

Jul 9, 2008

Appl. No.:

12/452450

Inventors:

George Wells - St. Louis MO, US
Ebenezer Satyaraj - Wildwood MO, US

Assignee:

Nestec SA - Vevey

International Classification:

A61K 39/00
A61K 39/395
C07K 16/00
C12P 21/08
G01N 33/53

US Classification:

4241301, 4241331, 4241391, 435 71, 5303871, 5303873

Abstract:

Compositions suitable for reducing symptoms of an allergic response to environmental allergens comprising molecules that specifically inhibit the ability of the allergen to bind to mast cells in an animal predisposed to having an allergic response to the allergen and methods for reducing such symptoms comprising contacting a source of the environmental allergen with such compositions. Kits, packages, medicaments, and means of communicating about the compositions and methods are also provided.